Scroll down to see more

About Laekna

Stock Code: 2105.HK

Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapies to cancer, metabolic diseases and liver fibrosis patients worldwide.

As of December 31, 2023, we have initiated six clinical trials for Afuresertib (LAE002), LAE001 and LAE005 for the treatment of breast cancer, prostate cancer, ovarian cancer and PD-1/ PD-L1 drug-resistant solid tumors to address the unmet medical needs. Among these six clinical trials, three are multi-regional clinical trials (MRCTs). Afuresertib is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the only two AKT inhibitors in or completed the pivotal-stage clinical development for anti-cancer treatment globally.

Laekna’s internal drug discovery platform has discovered 14 drug candidates. LAE102 is our internally discovered antibody against ActRIIA. We’ve obtained IND approvals from the FDA and the CDE in relation to obesity. Blocking Activin-ActRII pathway could promote skeletal muscle regeneration and decrease fat mass. Laekna team has accumulated tremendous experience and deep know-how in this specific field and is developing more drug candidates (LAE103 and LAE123) to maximize the value of targeting ActRII receptors.

Laekna, Inc. was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) on June 29, 2023, with the stock code 2105.HK.

Our Vision
Our Vision

Let Health


Your Choice

Core Management Team
Scientific Advisory Board
Peter ten Dijke
  • Last :Peter ten Dijke
  • Next :Jeff Porter
Core Inverstors
Honors & Awards
  • 2024

    PCIC:2024 Person of The Year

  • 2023

    Zhangjiang Life Science Industry New Prominent

    2023 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises

    Annual Innovation Award

    Most Valuable Pharmaceutical and Healthcare Company

    bioPR 2023 Best Corporate Video

    ZHANGJIANG GROUP Annual Influential Tech-Inno Startup

  • 2022

    2022 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises

    2022 Pioneers: The Scientists

    KPMG China Future 50 - Biotech

  • 2021

    2021 China Corporate Social Responsibility Virtual Summit - CSR Good Practice

    2021 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises

    Pioneers to the Star 2021 Biomedicine Pioneer-10

    Frost & Sullivan 2021 Top 100 Technology Leaders - Top 50 Innovative Technology Leaders

  • 2020

    Top 20 Disruptive Technologies in Cancer

  • 2019

    China Healthcare Industry Investment and Financing Honor List: Top 20 Emerging Healthcare Companies

  • 2018

    2018 Insights Zhangjiang Top 100

图片3 图片4
  • Last:Peter ten Dijke
  • Next:Jeff Porter
  • Last:Peter ten Dijke
  • Next:Jeff Porter
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation



Follow us on Linkedin